Tags : ImmuPharma

PharmaShots: COVID-19 Healthcare News Monthly Updates – June 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Avion Signs an Exclusive License Agreement with ImmuPharma to Develop

Shots: Immuphrama to receive $70M milestones including $5M as regulatory & $65M as commercialization milestones and up to 17% royalties on pre-specified annual US sales targets. ImmuPharma retains all rights to commercialize Lupuzor outside the US and receives an additional $5M on approval of Lupuzor for each additional indication (Ex- Lupus) Avion to get an […]Read More